US5179112A
(en)
*
|
1985-04-17 |
1993-01-12 |
Ici Americas Inc. |
Heterocyclic amide derivatives and pharmaceutical use
|
DE3650567T2
(de)
*
|
1985-10-17 |
1997-02-20 |
Zeneca Inc |
Medizinische Indol- und Indazol-Ketosulfonderivate
|
GB8623429D0
(en)
*
|
1985-10-17 |
1986-11-05 |
Ici America Inc |
Carboximide derivatives
|
ZA892643B
(en)
*
|
1988-04-14 |
1989-12-27 |
Ici America Inc |
Carbocyclic compounds
|
GB8911854D0
(en)
*
|
1989-05-23 |
1989-07-12 |
Ici Plc |
Heterocyclic compounds
|
US4965066A
(en)
*
|
1989-06-06 |
1990-10-23 |
E. I. Du Pont De Nemours And Company |
Intranasal administration of 3,3-disubstituted indolines
|
DK0455596T3
(da)
*
|
1990-05-04 |
1994-11-28 |
Ciba Geigy Ag |
Substituerede indoler
|
GB9026427D0
(en)
*
|
1990-12-05 |
1991-01-23 |
Ici Plc |
Chemical process
|
IL100091A
(en)
*
|
1990-12-12 |
1998-08-16 |
Zeneca Ltd |
Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
|
GB9027018D0
(en)
*
|
1990-12-12 |
1991-01-30 |
Ici Plc |
Heterocyclic compounds
|
EP0511477B1
(en)
*
|
1991-03-11 |
1996-07-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Indole derivatives
|
DE4123341A1
(de)
*
|
1991-07-15 |
1993-01-21 |
Thomae Gmbh Dr K |
Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
|
IT1251144B
(it)
*
|
1991-07-30 |
1995-05-04 |
Boehringer Ingelheim Italia |
Derivati del benzimidazolone
|
US5334597A
(en)
*
|
1991-10-17 |
1994-08-02 |
Merck Frosst Canada, Inc. |
Indole carbamates as leukotriene antagonists
|
EP0539329A1
(de)
*
|
1991-10-25 |
1993-04-28 |
Ciba-Geigy Ag |
Acetylen-Verbindungen, verwendbar als Leukotrien-Antagonisten
|
ES2072125T3
(es)
*
|
1991-10-25 |
1995-07-01 |
Ciba Geigy Ag |
Procedimiento para la obtencion de indoles substituidos.
|
US5272169A
(en)
*
|
1992-03-27 |
1993-12-21 |
The Dupont Merck Pharmaceutical Company |
(N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
|
US5217983A
(en)
*
|
1992-03-27 |
1993-06-08 |
Du Pont Merck Pharmaceutical Company |
(N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
|
GB9207236D0
(en)
*
|
1992-04-02 |
1992-05-13 |
Grosvenor Power Services Ltd |
Treatment of liquids
|
US5280039A
(en)
*
|
1992-11-04 |
1994-01-18 |
Pfizer Inc. |
Bicyclic carbamates and methods of treating inflammatory diseases using the same
|
US5439929A
(en)
*
|
1994-03-01 |
1995-08-08 |
Pfizer Inc. |
Bicyclic carbamates, pharmaceutical compositions and use
|
GB9415997D0
(en)
*
|
1994-08-08 |
1994-09-28 |
Merck Sharp & Dohme |
Therapeutic agents
|
EP0702004A2
(de)
*
|
1994-09-15 |
1996-03-20 |
Ciba-Geigy Ag |
2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
|
ES2108641B1
(es)
*
|
1995-07-31 |
1998-08-16 |
Menarini Lab |
Sulfonimidas quinolonicas con accion antagonista de los leucotrienos.
|
CZ248798A3
(cs)
*
|
1996-02-08 |
1999-01-13 |
Merck And Co., Inc. |
Farmaceutický prostředek
|
DE19610882A1
(de)
*
|
1996-03-20 |
1997-09-25 |
Dresden Arzneimittel |
Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US6630496B1
(en)
|
1996-08-26 |
2003-10-07 |
Genetics Institute Llc |
Inhibitors of phospholipase enzymes
|
GB9723985D0
(en)
*
|
1997-11-14 |
1998-01-14 |
Zeneca Ltd |
Pharmaceutical compositions
|
GB9726735D0
(en)
*
|
1997-12-18 |
1998-02-18 |
Zeneca Ltd |
Pharmaceutical compositions
|
WO1999036422A1
(en)
|
1998-01-14 |
1999-07-22 |
The Uab Research Foundation |
Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
|
US6861448B2
(en)
*
|
1998-01-14 |
2005-03-01 |
Virtual Drug Development, Inc. |
NAD synthetase inhibitors and uses thereof
|
US6673827B1
(en)
|
1999-06-29 |
2004-01-06 |
The Uab Research Foundation |
Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
|
US6828344B1
(en)
|
1998-02-25 |
2004-12-07 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
US6916841B2
(en)
*
|
1998-02-25 |
2005-07-12 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
US6500853B1
(en)
|
1998-02-28 |
2002-12-31 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
YU59600A
(sh)
|
1998-03-31 |
2002-12-10 |
The Institute For Pharmaceutical Discovery Inc. |
Supstituisane indolalkanoidske kiseline
|
DE19821002A1
(de)
*
|
1998-05-11 |
1999-11-18 |
Dresden Arzneimittel |
Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US6262066B1
(en)
|
1998-07-27 |
2001-07-17 |
Schering Corporation |
High affinity ligands for nociceptin receptor ORL-1
|
US6194432B1
(en)
*
|
1998-10-13 |
2001-02-27 |
Fred D. Sheftell |
Prevention and treatment of migraine, cluster and other recurrent headaches using leukotriene antagonist drugs
|
TNSN99224A1
(fr)
|
1998-12-01 |
2005-11-10 |
Inst For Pharm Discovery Inc |
Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
|
WO2001007031A1
(fr)
*
|
1999-07-26 |
2001-02-01 |
Shionogi & Co., Ltd. |
Derives de benzene, compositions immunostimulantes ou agents de retablissement de la pharmacosensibilite les contenant
|
IT1320162B1
(it)
|
2000-02-09 |
2003-11-18 |
Rotta Research Lab |
Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
|
IL140096A0
(en)
*
|
2000-12-05 |
2002-02-10 |
Internat Specialty Products Is |
Process for preparation of zafirlukast
|
US7183410B2
(en)
*
|
2001-08-02 |
2007-02-27 |
Bidachem S.P.A. |
Stable polymorph of flibanserin
|
US20030060475A1
(en)
*
|
2001-08-10 |
2003-03-27 |
Boehringer Ingelheim Pharma Kg |
Method of using flibanserin for neuroprotection
|
US10675280B2
(en)
|
2001-10-20 |
2020-06-09 |
Sprout Pharmaceuticals, Inc. |
Treating sexual desire disorders with flibanserin
|
UA78974C2
(en)
*
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
CN100528849C
(zh)
*
|
2003-01-13 |
2009-08-19 |
大日本住友制药株式会社 |
不含1,2-二氯乙烷的唑尼沙胺晶体的制备方法以及唑尼沙胺高纯晶体
|
US20090317476A1
(en)
*
|
2003-07-31 |
2009-12-24 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026882A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
|
CA2537185A1
(en)
*
|
2003-08-29 |
2005-03-10 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type-iv
|
GB0324763D0
(en)
*
|
2003-10-23 |
2003-11-26 |
Oxagen Ltd |
Use of compounds in therapy
|
US20050113410A1
(en)
*
|
2003-11-03 |
2005-05-26 |
Mark Tawa |
Pharmaceutical salts of zafirlukast
|
EP1694655A2
(en)
*
|
2003-11-26 |
2006-08-30 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
US20050239798A1
(en)
*
|
2004-04-22 |
2005-10-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for the treatment of premenstrual and other female sexual disorders
|
WO2005102342A1
(en)
*
|
2004-04-22 |
2005-11-03 |
Boehringer Ingelheim International Gmbh |
New pharmaceutical compositions for the treatment of sexual disorders ii
|
US20060025420A1
(en)
*
|
2004-07-30 |
2006-02-02 |
Boehringer Ingelheimn International GmbH |
Pharmaceutical compositions for the treatment of female sexual disorders
|
JP2008511569A
(ja)
*
|
2004-09-03 |
2008-04-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
注意欠如活動過多障害の治療方法
|
EP1817034A1
(en)
|
2004-10-25 |
2007-08-15 |
Schering Corporation |
M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
|
MX2007010112A
(es)
*
|
2005-02-25 |
2007-10-12 |
Ono Pharmaceutical Co |
Compuesto indol y uso del mismo.
|
WO2006096462A1
(en)
*
|
2005-03-03 |
2006-09-14 |
Elan Pharma International Limited |
Nanoparticulate compositions of heterocyclic amide derivatives
|
CA2599937A1
(en)
*
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
|
JP2008538741A
(ja)
*
|
2005-03-04 |
2008-11-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
鬱病の治療用及び/又は予防用の医薬組成物
|
WO2006096439A2
(en)
*
|
2005-03-04 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
|
JP2008540356A
(ja)
*
|
2005-05-06 |
2008-11-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
薬物乱用の治療方法
|
EP1888071A1
(en)
*
|
2005-05-19 |
2008-02-20 |
Boehringer Ingelheim International GmbH |
Method for the treatment of drug-induced sexual dysfunction
|
WO2006125041A1
(en)
*
|
2005-05-19 |
2006-11-23 |
Boehringer Ingelheim International Gmbh |
Method for the treatment of sexual dysfunctions due to medical conditions
|
ZA200800901B
(en)
|
2005-07-14 |
2010-05-26 |
Takeda San Diego Inc |
Histone deacetylase inhibitors
|
JP2009503020A
(ja)
|
2005-08-03 |
2009-01-29 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
肥満症の治療におけるフリバンセリンの使用
|
ES2246742B1
(es)
*
|
2005-09-06 |
2007-02-01 |
Prous Institute For Biomedical Research S.A. |
Uso de un derivado de imidazol.
|
US7915286B2
(en)
|
2005-09-16 |
2011-03-29 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
BRPI0617673C1
(pt)
*
|
2005-10-19 |
2012-05-22 |
Ranbaxy Lab Ltd |
composições de inibidores de fosfodiesterase do tipo iv
|
JP2009513604A
(ja)
*
|
2005-10-29 |
2009-04-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
|
US20070123540A1
(en)
*
|
2005-10-29 |
2007-05-31 |
Angelo Ceci |
Sexual desire enhancing medicaments comprising benzimidazolone derivatives
|
US20070105869A1
(en)
*
|
2005-11-08 |
2007-05-10 |
Stephane Pollentier |
Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
|
WO2007096694A1
(es)
*
|
2006-02-22 |
2007-08-30 |
Ramiro Vergara |
Asociacion de principios activos neuroactivadores
|
PE20080090A1
(es)
*
|
2006-05-09 |
2008-03-14 |
Boehringer Ingelheim Int |
Flibanserina para el tratamiento de trastornos post-menopausicos del deseo sexual
|
DE602007004615D1
(de)
|
2006-06-30 |
2010-03-18 |
Boehringer Ingelheim Pharma |
Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
|
US20090318469A1
(en)
*
|
2006-07-14 |
2009-12-24 |
Boehringer Ingelheim International Gmbh |
Use of Flibanserin for the Treatment of Sexual Disorders in Females
|
CN101104601B
(zh)
*
|
2006-07-14 |
2011-01-26 |
海南盛科生命科学研究院 |
一种新的扎鲁司特重要中间体的制备方法
|
DK2046740T3
(da)
|
2006-07-22 |
2012-08-20 |
Oxagen Ltd |
Forbindelser med CRTH2-antagonistisk virkning
|
CL2007002214A1
(es)
*
|
2006-08-14 |
2008-03-07 |
Boehringer Ingelheim Int |
Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
|
KR20090042967A
(ko)
*
|
2006-08-14 |
2009-05-04 |
베링거 인겔하임 인터내셔날 게엠베하 |
플리반세린 제형 및 이의 제조방법
|
AU2007287639A1
(en)
*
|
2006-08-25 |
2008-02-28 |
Boehringer Ingelheim International Gmbh |
Controlled release system and method for manufacturing the same
|
US20100029728A1
(en)
*
|
2006-09-22 |
2010-02-04 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
EA200900472A1
(ru)
*
|
2006-09-22 |
2009-10-30 |
Ранбакси Лабораторис Лимитед |
Ингибиторы фосфодиэстеразы iv типа
|
EP1958947A1
(en)
|
2007-02-15 |
2008-08-20 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type 4
|
EP2124944B1
(en)
*
|
2007-03-14 |
2012-02-15 |
Ranbaxy Laboratories Limited |
Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
|
EP2124943A1
(en)
*
|
2007-03-14 |
2009-12-02 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
|
WO2009018280A2
(en)
*
|
2007-07-30 |
2009-02-05 |
Auspex Pharamaceuticals, Inc. |
Substituted indoles
|
PE20091188A1
(es)
|
2007-09-12 |
2009-08-31 |
Boehringer Ingelheim Int |
Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
|
US20090149662A1
(en)
*
|
2007-12-05 |
2009-06-11 |
Raghupathi Reddy Anumula |
Processes for preparing zafirlukast
|
CN101951886A
(zh)
*
|
2007-12-21 |
2011-01-19 |
先灵-普劳健康护理产品公司 |
增强羟甲唑啉的光稳定性
|
WO2009090414A1
(en)
|
2008-01-18 |
2009-07-23 |
Oxagen Limited |
Compounds having crth2 antagonist activity
|
US7750027B2
(en)
*
|
2008-01-18 |
2010-07-06 |
Oxagen Limited |
Compounds having CRTH2 antagonist activity
|
JP2011509990A
(ja)
*
|
2008-01-22 |
2011-03-31 |
オキサジェン リミテッド |
Crth2アンタゴニスト活性を有する化合物
|
EP2240444A1
(en)
*
|
2008-01-22 |
2010-10-20 |
Oxagen Limited |
Compounds having crth2 antagonist activity
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
US20110112134A1
(en)
*
|
2008-05-16 |
2011-05-12 |
Amira Pharmaceuticals, Inc. |
Tricyclic Antagonists of Prostaglandin D2 Receptors
|
WO2010008864A2
(en)
*
|
2008-06-24 |
2010-01-21 |
Amira Pharmaceuticals, Inc. |
Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
|
WO2010085820A2
(en)
*
|
2009-01-26 |
2010-07-29 |
Amira Pharmaceuticals, Inc. |
Tricyclic compounds as antagonists of prostaglandin d2 receptors
|
EP2443134A2
(en)
|
2009-06-16 |
2012-04-25 |
Schering Corporation |
NOVEL [3,2-c]HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES THEREOF
|
EP2651930B1
(en)
*
|
2010-12-16 |
2015-10-28 |
Boehringer Ingelheim International GmbH |
Biarylamide inhibitors of leukotriene production
|
US9657033B2
(en)
|
2012-05-08 |
2017-05-23 |
Lycera Corporation |
Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
|
US9394315B2
(en)
|
2012-05-08 |
2016-07-19 |
Lycera Corporation |
Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
WO2014012954A1
(en)
|
2012-07-18 |
2014-01-23 |
Takeda Gmbh |
Treatment of partly controlled or uncontrolled severe asthma
|
CN103396353B
(zh)
*
|
2013-08-23 |
2015-05-20 |
海南通用三洋药业有限公司 |
一种扎鲁司特无定型态及其制备方法
|
GB201322273D0
(en)
|
2013-12-17 |
2014-01-29 |
Atopix Therapeutics Ltd |
Process
|
US9663502B2
(en)
*
|
2013-12-20 |
2017-05-30 |
Lycera Corporation |
2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
|
US9809561B2
(en)
|
2013-12-20 |
2017-11-07 |
Merck Sharp & Dohme Corp. |
Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
|
JP2017503814A
(ja)
|
2014-01-22 |
2017-02-02 |
タケダ ゲー・エム・ベー・ハーTakeda GmbH |
部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のpde4インヒビターを用いた(およびロイコトリエン調節薬と組み合わせて用いた)治療
|
CN106132422A
(zh)
|
2014-02-27 |
2016-11-16 |
莱斯拉公司 |
使用视黄酸受体相关孤儿受体γ的激动剂的过继细胞疗法&相关治疗方法
|
GB201407807D0
(en)
|
2014-05-02 |
2014-06-18 |
Atopix Therapeutics Ltd |
Polymorphic form
|
GB201407820D0
(en)
|
2014-05-02 |
2014-06-18 |
Atopix Therapeutics Ltd |
Polymorphic form
|
AU2015256190B2
(en)
|
2014-05-05 |
2019-08-15 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
EP3209641A4
(en)
|
2014-05-05 |
2018-06-06 |
Lycera Corporation |
Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
|
JP2018510135A
(ja)
|
2015-02-11 |
2018-04-12 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
RORγT阻害剤としての置換ピラゾール化合物及びその使用
|
CA2982847A1
(en)
|
2015-05-05 |
2016-11-10 |
Lycera Corporation |
Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
|
KR20180025894A
(ko)
|
2015-06-11 |
2018-03-09 |
라이세라 코퍼레이션 |
Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
|
WO2017075178A1
(en)
|
2015-10-27 |
2017-05-04 |
Merck Sharp & Dohme Corp. |
SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
EP3368535B1
(en)
|
2015-10-27 |
2020-12-02 |
Merck Sharp & Dohme Corp. |
Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
|
EP3368539B1
(en)
|
2015-10-27 |
2020-12-02 |
Merck Sharp & Dohme Corp. |
Substituted indazole compounds as ror gamma t inhibitors and uses thereof
|
EP3168570A1
(fr)
|
2015-11-10 |
2017-05-17 |
Primetals Technologies France SAS |
Méthode de mesure de planéité d'un produit métallique et dispositif associé
|
KR101713303B1
(ko)
*
|
2015-12-24 |
2017-03-07 |
강원대학교산학협력단 |
2h-인다졸 유도체의 제조방법
|
EP3585809A4
(en)
|
2017-01-30 |
2021-02-24 |
Western New England University |
THIOLISOMERASE INHIBITORS AND USES THEREOF
|
WO2019130334A1
(en)
|
2017-12-28 |
2019-07-04 |
Council Of Scientific & Industrial Research |
Process for the preparation of zafirlukast and analogs thereof
|
CN109438414B
(zh)
*
|
2018-10-24 |
2021-03-16 |
常州大学 |
一种制备苯并1,3-氧硫杂环己烷-4-酮的方法
|
CN110183371B
(zh)
*
|
2019-04-11 |
2022-06-14 |
南京医科大学 |
一种扎鲁司特中间体的制备工艺
|
EP4041224A1
(en)
|
2019-10-08 |
2022-08-17 |
Rigshospitalet |
Zafirlukast derivatives for use as contraceptive agents
|
EP4340828A1
(en)
|
2021-05-19 |
2024-03-27 |
Quercis Pharma AG |
Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
|
WO2023214391A1
(en)
|
2022-05-06 |
2023-11-09 |
Quercis Pharma AG |
Method for treating cancers and neurological diseases using quercetin-containing compositions
|